title: Adverse reactions of Topiramate and Lamotrigine in children.
abstract: OBJECTIVE
  To review the adverse drug reactions (ADRs) of Topiramate and Lamotrigine among children in Israel, and to compare the two drugs, based on their side effect profile and tolerability among this population.
  
  
  METHODS
  We performed a cross-sectional study. Four paediatric neurologists from three different tertiary medical centres in Israel documented all cases of children from birth to the age 18 years, treated with Topiramate and/or Lamotrigine in their respective outpatient clinics and hospital wards. All present ADRs and their characteristics were recorded.
  
  
  RESULTS
  Reports on 45 and 65 children treated with Topiramate and Lamotrigine respectively, were received. Half of the children treated with Topiramate suffered from one or more ADRs, as opposed to one-third of the children treated with Lamotrigine (p = 0.03). Most reactions were considered mild to moderate. There were no deaths or hospitalisations, but the drug had to be discontinued in about 10% of the patients due to ADRs. Most Topiramate and Lamotrigine ADRs appeared early in the treatment and were more frequent when Topiramate was an add-on versus a monotherapy drug. Most ADRs of both Topiramate and Lamotrigine were related to the central nervous system; while poor appetite, drowsiness, speech difficulties and weight loss were observed only with Topiramate, and rash and headaches only with Lamotrigine. Nervousness and seizure aggravation were more frequent ADRs of Topiramate whereas sleep disturbances were observed more in children treated with Lamotrigine.
  
  
  CONCLUSIONS
  Results of this study indicate that Lamotrigine causes ADRs less frequently than Topiramate; however both medications are generally well tolerated. Topiramate and Lamotrigine differ in their central nervous system side effect profile.
authors.affiliation: Pharmacy Services, Soroka Medical Center, Be'er Sheva, Israel. tamars@clalit.org.il
authors.forename: Tamar
authors.initials: T
authors.lastname: Shechter
authors.forename: Zamir
authors.initials: Z
authors.lastname: Shorer
authors.forename: Uri
authors.initials: U
authors.lastname: Kramer
authors.forename: Tally
authors.initials: T
authors.lastname: Lerman-Sagie
authors.forename: Elisheva
authors.initials: E
authors.lastname: Ronen
authors.forename: Rimona
authors.initials: R
authors.lastname: Rotem
authors.forename: Rafael
authors.initials: R
authors.lastname: Gorodischer
mesh_terms: D000293:Adolescent; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D016903:Drug Monitoring / Q000379:methods / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D005221:Fatigue / Q000139:chemically induced; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D000077213:Lamotrigine; D015337:Multicenter Studies as Topic; D012894:Sleep Stages / Q000187:drug effects; D013997:Time Factors; D000077236:Topiramate; D016896:Treatment Outcome; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015431:Weight Loss / Q000187:drug effects
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D000077236:Topiramate; D005632:Fructose; D000077213:Lamotrigine